**Small cell carcinoma of the bladder: A population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy**

Justin Oh, MD[1,2]; Bernhard Eigl, MD[3]; Peter C. Black, MD[4]; Tom Pickles, MD[1,2]; Carlos Villamil, MD[5]; Katherine Sunderland, MPH[6]; Scott Tyldesley, MD[1,2]

[1]Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada;
[2]Department of Radiation Oncology, British Columbia Cancer – Vancouver Centre, Vancouver, BC, Canada;
[3]Department of Medical Oncology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada;
[4]Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; [5]Department of Pathology and Laboratory Medicine, British Columbia Cancer – Vancouver Centre, Vancouver, BC, Canada;
[6]Cancer Surveillance and Outcomes, Population Oncology, British Columbia Cancer

**Corresponding author:** Dr. Scott Tyldesley, BC Cancer– Department of Radiation Oncology, Vancouver, BC, Canada; Styldesl@bccancer.bc.ca

\*\*\*

**Abstract**

**Introduction:** We aimed to describe the oncological outcomes after radical cystectomy and chemo-radiation for localized small cell bladder cancer (SCBC).

**Methods:** This population-based analysis of localized SCBC from 1985–2018 in British Columbia included an analysis (analysis 1) of cancer-specific survival (CSS) and overall survival (OS) of patients treated with curative-intent radical cystectomy (RC) and radiation (RT), and an analysis (analysis 2) of CSS and OS in patients treated with RC and chemoRT consistent with the SCBC Canadian consensus guideline.

**Results:** Seventy-seven patients who were treated with curative intent were identified: 33 patients had RC and 44 had RT. For analysis 1, five-year OS was 29% and 39% for RC and RT, respectively (p=0.51), and five-year CSS was 35% and 52% for RC and RT, respectively (p=0.29). On multivariable analysis, higher Charlson comorbidity index (CCI) and the lack of neoadjuvant chemotherapy (NACHT) were associated with worse OS, while higher CCI and Eastern Cooperative Oncology Group (ECOG) were associated with worse CSS. For analysis 2,

five-year OS was 56% and 58% for the RC and chemoRT groups, respectively (p=0.90), and five-year CSS was 56% for RC and 71% for chemoRT (p=0.71). Four of 42 (9.5%) chemoRT patients had RC at relapse.

**Conclusions:** SCBC is a rare entity with a poor prognosis. RC and chemoRT offer similar CSS and OS for localized SCBC, even when focusing the analysis on patients treated according to the modern consensus guidelines. NACHT should be considered for eligible patients. Both chemoRT and RC treatment options should be discussed with patients with SCBC.

## Introduction

Small cell cancer of the bladder (SCBC), a poorly differentiated neuroendocrine tumor, is an uncommon entity associated with a poor prognosis.[1-4] The incidence of SCBC is rising, but there is paucity of literature regarding the optimal management of SCBC. Both the National Comprehensive Cancer Network (NCCN) and the Canadian Bladder Cancer Guidelines have proposed treatment options for localized SCBC, defined as disease confined to the pelvis and associated lymph nodes, that include neoadjuvant chemotherapy followed by radical cystectomy (RC) and definitive chemoradiation (chemoRT) with 4 – 6 cycles of platinum-based chemotherapy (CHT) and 60Gy Equivalent Dose 2Gy (EQD2) of radiation. [5-7]

Previously, our center published a case series of patients who were treated with chemoradiation between 1985 and 1996, demonstrating a 2 year and 5 year OS of 70% and 44% respectively.[8] Since then, there has been a limited number of retrospective studies comparing the outcomes between RC and chemoRT, but no prospective randomized trials addressing the optimal local therapy.[2,9,10]

This study describes the cohort characteristics, treatment patterns, and oncologic outcomes of localized SCBC patients after both RC and curative intent RT in a population-based cohort. Two analysis were performed: One including all curative RC and RT patients (analysis 1), and one focusing on those patients who had RC or RT in accordance with the Canadian consensus guidelines (analysis 2).[6]

## Methods

### *Study design and patient selection*

A population-based review of patients who received RC or chemoRT from 1985 to 2018 for pure or mixed SCBC in the province was performed. BC Cancer consists of six regional centers and provides all radiation therapy in the province of British Columbia. All incident cancers are registered in a central cancer registry, which includes all pathology reports from both the TURBT and cystectomy specimens. All radiotherapy and chemotherapy details in the province

have been prospectively collected since 1982 and 1998 respectively. All surgical records from 2012 have been captured electronically in the Canadian Institute for Health Information (CIHI) discharge summary data. Patients who had distant metastasis or palliative treatment upfront were excluded. This study received University of British Columbia (UBC) ethics approval (H18-02234).

## Data abstraction and outcomes

All incident cases of neuroendocrine cancer of the bladder captured in the BC Cancer Registry were identified from 1985 to 2018. Any primary bladder histology with a small cell component was included in the study. The pathology reports were reviewed by a BC Cancer sanctioned expert pathologist to ensure that they meet the criteria for SCBC. All the patients who received RT for SCBC in the province after diagnosis were identified using the BC Cancer Agency Information System (CAIS). The charts with either a cystectomy or TURBT specimen showing small cell histology were reviewed. For the years 2012 to 2018, the provincial hospital discharge summary data was used to help verify the surgical patients and to supplement CAIS data after 2012. The proportion of surgical cases that were missed using the cancer registry and CAIS for the years 2012 to 2018 were assessed to extrapolate the potential missing surgical cases prior to 2012. Data abstracted included age, sex, Eastern Cooperative Oncology Group Performance Status (ECOG), comorbidities, T stage, N stage, year of diagnosis, type of surgery, radiation technique, dose, fractionation, and type of chemotherapy. Clinical staging was assigned in accordance with the American Joint Committee on Cancer (AJCC) 8th edition based on the transurethral resection of bladder (TURBT), physical examination, and imaging findings at diagnosis. Charlson comorbidity index score was calculated based on age and comorbidities at diagnosis.[11] Outcomes were determined using the reports from imaging studies and follow up notes. Death date and the cause of death were available from the BC Cancer Registry.

## Outcomes and data analysis

Two analyses were performed: Analysis 1 compared RC and curative intent RT cases and analysis 2 was restricted to cases in which small cell cancers patients were treated according to the consensus guidelines.[6] For analysis 2, inclusion implied that small cell histology was identified on TURBT, neoadjuvant CHT (NACHT) was given prior to RC, and RT dose was within 15% of the 60Gy equivalent 2Gy fraction dose (EQD2) using A/B of 10, and at least $4 - 6$ cycles of CHT was delivered. The A/B ratio was determined based on the prior SCLC literature.[12,13] For the RT group, NACHT and adjuvant CHT (ACHT) were defined as any cycle of CHT given prior to or after RT respectively. Primary outcome for both analyses was overall survival (OS) as defined from the date of diagnosis to the date of death from any cause. Secondary outcomes included cancer specific survival (CSS), rate of brain metastasis, and the rate of salvage therapy. For analysis 1, univariate Cox regression analysis (UVA) was performed

to assess the association of demographic, clinical, and treatment variables with OS and CSS. Multivariate Cox regression analysis (MVA) was performed to compare the OS and CSS between the surgical and RT groups, and the patients who did or did not receive NACHT or ACHT. Clinical stage and treatment group were included in the MVA. All variables with p<0.25 in univariate analysis were entered in backward stepwise regression analysis for the MVA. When treatment group and stage were forced in the model, the entry criterion was p<0.25 and the removal criterion was p≥0.15. For analysis 2, UVA and MVA cox regression were not performed for OS and CSS as the event counts were low and the proportional hazards (PH) assumptions were violated. Instead, the univariate OS and CSS results were reported as K-M estimates. Statistical analysis was performed with SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

**Results**

*Patient and disease characteristics*
In total, 188 patients were identified (Fig 1). Seventy-six patients received radiation therapy for localized SCBC: Thirty-two were excluded due to palliative intent of RT (prospectively specified in the database) and dose of radiotherapy (defined as an EQD2 dose of < 30 Gy). The CIHI system was able to identify 1 additional surgical patient who was registered under the CAIS system but not flagged as a surgical patient during the 2012 to 2018 era (6% of surgery cases during this era).

For analysis 1, 77 patients were identified: Forty-four (57%) patients had chemoRT and 33 (43%) patients had RC. Sixty-eight (88%) patients had SCBC histologic diagnosis on trans-urethral resection of the bladder tumour (TURBT), and 9 (12%) had urothelial histologic diagnosis from TURBT which was changed to SCBC after RC. Seventy-six of 77 (99%) patients had a staging workup with at least a CT abdomen/pelvis, and either a CT chest or chest X-ray. Fifty-nine of 77 (77%) had a bone scan, 29 (38%) had a brain CT/MRI, and 7 (10%) had an FDG PET scan, which only became available for cancer patients in BC in 2001. All but one case had adequate information recorded in the chart to assign stage, and the 1 patient was treated as limited stage in the medical record and was included as localized stage.
For analysis 2, 33 patients had small cell diagnosed on TURBT, of whom 10 had NACHT prior to RC and 23 had NACHT/ACT in addition to RT.
Demographic data and disease characteristics for both analyses are presented in Table 1.

*Treatment characteristics*
In the RT group, one patient had received a curative dose of radiotherapy (66Gy/33 fractions) alone. All chemoRT patients received some neoadjuvant (n=37, 84%) or adjuvant CHT (n=6, 14%) in addition to the concurrent CHT. The majority of RC cases received either neoadjuvant (n=10, 30%) or adjuvant (n=16, 49%) chemotherapy, 10 of whom were in analysis 2. Out of the 7 that did not receive chemotherapy in RC group, there was a plan to use adjuvant chemotherapy

*CUAJ* – Original Research
Oh et al
**Long-term outcomes post-RC & chemo-radiation in bladder cancer**

in 57% (4/7), but post-op complications and/or a functional decline prohibited its use. In the remaining cases, there was no record of a medical oncology consult in the charts. Of the 24 patients who had small cell histology identified on TURBT, 5 did not receive CHT. Cisplatin-based chemotherapy was the most commonly used regimen in both groups. The majority of patients were treated with cis-platinum and etoposide (n=51, 66%), and the remaining cases were treated with carboplatin and etoposide (n=13, 16.9%), CAV (cyclophosphamide, doxorubicin, and vincristine) based regimens (n=6, 7.8%), or no chemotherapy (n=7, 9.1%).

Median Equivalent Dose in 2Gy (EQD2) for the analysis 1 was 52Gy (interquartile range [IQR] 46 to 58Gy) and analysis 2 was 58Gy (IQR 54 – 60). Prophylactic cranial irradiation (PCI) was used in 7 of 42 (17%) of the chemoRT group and 1 of 35 (3%) of the RC group. Median dose for PCI was 25Gy (IQR 25 – 25Gy). EQD2 for PCI was 21Gy using an A/B ratio of 10. Treatment characteristics are in Table 1.

### *Survival outcomes*

*Analysis 1: All cases treated with curative intent*
For analysis 1, the 5-year OS was 39% for RT and 29% RC groups (Figure 2) (NS). Median survivals were 2.8 years (95% confidence interval [CI] 1.9 – 6.6) for RT and 2.2 years (95% CI 1.4 – 3.4) for RC groups (p=0.51). There was no significant difference in OS between chemoRT and RC group in the UVA. Higher CCI remained as a significant variable in the OS MVA (Table 3). NACHT was associated with longer median OS compared to the adjuvant/no chemotherapy group (p=0.04).

CSS was 52% and 35% at 5 years for RT and RC group respectively (Figure 3). Median CSS was 6.3 years for chemoRT (95% CI 2.2 – not estimable) and was 3.3 years (95% CI 1.6 – 8.4) for RC groups (p=0.29). There was no significant difference in CSS between RT and RC group on UVA. Higher CCI and ECOG at diagnosis was also associated with worse CSS in MVA (Table 3).

Four of 42 (9.5%) chemoRT patients eventually required salvage cystectomy. One patient developed urothelial carcinoma, and the other 3 developed local recurrence of the SCBC. Of these four patients, one died of bladder cancer, 2 of 4 died of unrelated causes, and 1 is alive at last follow-up 6 years after the salvage cystectomy.

In total, 14 out of 77 patients (18%) developed brain metastasis, with a median time from diagnosis 17 months (range 9 – 38 months). Of these patients, 7 did not have baseline brain imaging prior to initial treatment, 1 did not receive any systemic therapy due to post-op complications, and 4 received PCI. In total, 8 patients had PCI: 1 had unknown stage at presentation, 1 had stage II disease, and the rest had stage IIIA/B disease.

*Analysis 2: All curative cases treated according to the modern Canadian consensus guideline*

There were 10 RC patients who had NACHT and 23 RT patients that received at least 60Gy EQD2 RT with chemotherapy in accordance with the consensus guideline. OS at 5 years in these patients was 56% for RC and 58% for RT respectively (p=0.9 on KM). CSS at 5 years in these patients was 56% for RC and 71% for RT respectively (p=0.71 on KM). Details of the cases in analysis 2 is shown in table 1.

**Discussion**

To our knowledge, this is the largest population-based retrospective comparison of curative intent RC and chemoRT for SCBC. Our study found that SCBC patients have a poor prognosis, and both curative intent treatment groups had a similar 5-year OS and CSS on univariate and multivariate analysis. Although the numbers of cases in both groups are small, multivariable analysis did not show a significant difference in OS and CSS between them. The observed five-year OS of 39% (n =44) in the current RT cohort is consistent with the previously published 5-year OS of 44% (n=14) at our center.

There is no prospective trial comparing RT and RC for SCBC to date. However, the reported small number of retrospective reviews are consistent with the findings of this study. A recent retrospective study based on National Cancer Database (NCDB) identified 856 patients with SCBC and found a similar finding with 5-year OS for chemoRT (24%) and surgery (24%).[9] However, the authors were not able to identify or compare many baseline characteristics, clinical staging, and chemotherapy use from the NCDB. Recently, an abstract was presented for a large retrospective study comparing chemoRT vs surgery across 26 institutions in the United Kingdom, which identified 409 patients with SCBC and found that median OS did not significantly differ between the chemoRT (30 months) and the RC (27 months), although again the ability to compare baseline prognostic and treatment parameters was limited.[14] Both of these larger retrospective studies are consistent with our finding of similar survival outcomes between chemoRT and surgery for SCBC.

In contrast, a smaller retrospective series (n=38) at Fox Chase Cancer Center suggested that patients who had RC had better OS and progression free survival (PFS) on univariate analysis compared to RT.[10] However, after accounting for age, histology, and stage, the MVA did not demonstrate significantly difference between the two treatment modalities. Despite the MVA, the authors noted that all of the longest survivors (n=7, as defined by 1.5 times 75% interquartile range overall survival) had radical cystectomy, and the institutional standard of therapy for localized SCBC remains neoadjuvant chemotherapy followed by RC.[10] The discrepancy may be due to selection bias or lack of baseline characteristic comparisons of the treatment groups. The study also did not consider censored patients who would have met the criteria for longest survivors if a longer follow-up were conducted. In the present analysis, there are equal numbers of long-term survivors after both RC and chemo-RT.

Our analysis supports the use of the current Canadian Consensus Guideline for the limited SCBC. A separate analysis was performed to reflect the current guideline, limiting the analysis to the RC patients who were diagnosed on TURBT only and received NACHT, and the RT patients that received near 60Gy EQD2 dose and 4 – 6 cycles of cisplatin. In this analysis, 5-year OS and CSS between the RC and RT groups were similar as well. Although direct comparison is limited by small numbers, 5-year OS and CSS in both RC and RT groups were seemingly better in analysis 2 than analysis 1. It is difficult to comment on whether the apparently better outcomes are due to treatment regimen or selection bias, but without a larger or prospective trial, limited SCBC management as proposed by the consensus guideline seems appropriate.

For the patients who are planned for radical cystectomy, the Canadian Consensus Guideline suggests NACHT. A retrospective study at MD Anderson demonstrated that pre-operative chemotherapy group (n=48) had improvement in OS and CSS compared to upfront RC group (n=47).[15] Authors suggested that some of the improvements in outcomes may be due to effective downstaging and early control of micrometastatic disease. In our RC cohort, 10/33 (30%) of all cases were treated with NACHT. Of the patients with a pre-RC diagnosis of SCBC, 11/24 (46%) had NACHT. All neoadjuvant CHT patients went onto planned RC while 4 patients could not receive planned adjuvant CHT due to post-op complications, suggesting that patients are better able to tolerate NACHT or that fit patients were selected for the purpose of NACHT. However, completion of RC or RT was an inclusion criterion in our analysis, and it is possible that some patients intended for a RC or RT after neoadjuvant CHT are excluded in our analysis due to disease progression. For primary RT treatment, the guideline suggests starting RT with cycle 1 – 2 of CHT.[16-18] In our RT cohort, 37/44 (84%) had NACHT, and 6/44 (14%) ACHT. Although the influence of the sequencing of CHT on the outcomes for RC and RT separately was not assessed, 5-year OS inclusive of both groups in the MVA was significantly longer for neoadjuvant group compared to the adjuvant group (HR 0.5, 95% CI 0.26 – 0.95, p<0.04). Given that there was no association between NACHT and CSS, this may suggest that more fit patients eligible for NACHT have better OS or that CSS analysis was not powered to detect such a difference. Thus, despite the limitation of the analysis, administration of NACHT may be the best approach for both the RC and RT group as per the Canadian consensus guideline based on the current study result and the biological rationale.

This study should be interpreted in the context of strengths and limitations. The retrospective nature of the study cannot adequately account for the confounding factors as well as a survivor bias as the patients were retrospectively identified. The long timespan of the study may also add to the variability in the staging investigations, which may not reflect the distribution of the clinical stages in the current era. The comprehensiveness of the database in identifying the surgical cohort may be limited as only the BC Cancer medical records could be accessed, although CIHI and CAIS registry were quite concordant for the years of overlap with

only 1 additional surgical patient identified by CIHI. Some of the TURBT or RC histology in the community would not have been reviewed centrally, and there may have been specimens that would have met the criteria for SCBC. Despite the limitations, the study has a relatively larger sample size in comparison to the previous single-institute studies, and a population-based design reduces treatment heterogeneity and referral bias and provides access to patient baseline characteristics and clinical staging that allow more balanced comparison of the treatment groups.

## Conclusions

Small cell cancer of the bladder (SCBC) is a rare entity with a poor prognosis. This study is the largest population-based retrospective comparison of the patients treated with curative RC and RT for limited SCBC. There was no significant difference in the overall survival or cancer specific survival between the two treatment groups, even when the comparisons were limited to the population treated by the most recent consensus guideline. NACHT showed better outcome compared to ACHT, consistent with the consensus guideline. Both RC and ChemoRT should be considered treatment options for localized SCBC.

## References

1. Holmang S, Borghede G, Johansson SL. Primary small cell carcinoma of the bladder: a report of 25 cases. *J Urol* 1995;153(6):1820-1822.
2. Pasquier D, Barney B, Sundar S, et al. Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. *Int J Radiat Oncol Biol Phys* 2015;92(4):904-910.
3. Grignon DJ, Ro JY, Ayala AG, et al. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. *Cancer* 1992;69(2):527-536.
4. Wang G, Xiao L, Zhang M, et al. Small cell carcinoma of the urinary bladder: a Clinicopathologic and Immunohistochemical analysis of 81 cases. *Hum Pathol* 2018.
5. Dores GM, Qubaiah O, Mody A, Ghabach B, Devesa SS. A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992-2010. *BMC Cancer* 2015;15:185.
6. Moretto P, Wood L, Emmenegger U, et al. Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). *Can Urol Assoc J* 2013;7(1-2):E44-56.
7. Dans M, Smith T, Back A, et al. NCCN Guidelines Insights: Palliative Care, Version 2.2017. *J Natl Compr Canc Netw* 2017;15(8):989-997.
8. Lohrisch C, Murray N, Pickles T, Sullivan L. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. *Cancer* 1999;86(11):2346-2352.
9. Fischer-Valuck BW, Rao YJ, Henke LE, et al. Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder. *Eur Urol Focus* 2018;4(6):900-906.
10. Jung K, Ghatalia P, Litwin S, et al. Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. *Clin Genitourin Cancer* 2017;15(3):e337-e343.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40(5):373-383.
12. Li-Ming X, Zhao LJ, Simone CB, 2nd, et al. Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer. *Radiother Oncol* 2017;125(2):331-337.
13. Yoon HG, Noh JM, Ahn YC, Oh D, Pyo H, Kim H. Higher thoracic radiation dose is beneficial in patients with extensive small cell lung cancer. *Radiat Oncol J* 2019;37(3):185-192.
14. Chau C, Rimmer Y, Law A, et al. 928PNational small cell bladder cancer audit: Results from 26 UK institutions. *Annals of Oncology* 2019;30(Supplement_5).
15. Lynch SP, Shen Y, Kamat A, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. *Eur Urol* 2013;64(2):307-313.

16. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. *J Clin Oncol* 2006;24(7):1057-1063.
17. Kalemkerian GP, Loo BW, Akerley W, et al. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. *J Natl Compr Canc Netw* 2018;16(10):1171-1182.
18. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1993;11(2):336-344.

## Figures and Tables

*Fig. 1.* Patients flowchart diagram. ACHT: adjuvant chemotherapy; CHT: chemotherapy; EQD2: equivalent dose in 2 Gy fractions; NACHT: neoadjuvant chemotherapy; RT: radiation therapy.

*Fig. 2.* Analysis 1. Kaplan-Meier curve for overall survival (OS) by initial treatment. CI: confidence interval; RT: radiation therapy.



| Treatment Group | 5-year survival (%) | Median OS (95% CI) | |
|---|---|---|---|
| Curative RT | 39% | 2.8 years (1.9 – 6.6) | log rank |
| Primary Surgery | 29% | 2.2 years (1.4 – 3.4) | p = 0.51 |

***Fig. 3.*** Analysis 1. Kaplan-Meier curve for cancer-specific survival (CSS) by initial treatment. CI: confidence interval; RT: radiation therapy.



| Treatment Group | 5-year survival | Median CSS (95% CI) | |
|---|---|---|---|
| Curative RT | 52% | 6.3 years (2.2 – not est.) | log rank |
| Primary Surgery | 35% | 3.3 years (1.6 – 8.4) | p = 0.29 |

***Fig. 4.*** Analysis 2. Kaplan-Meier curve for cancer-specific survival (CSS) by initial treatment. CI: confidence interval; NACHT: neoadjuvant chemotherapy; RT: radiation therapy.



| Treatment Group | 5-year survival | Median CSS (95% CI) | |
|---|---|---|---|
| ChemoRT | 71% | Not est. (4.5 – not est.) | log rank |
| NACHT Surgery | 56% | Not est. (2.2 – not est.) | p = 0.71 |

| Table 1. Demographic, disease, and treatment characteristics | | | | | |
|---|---|---|---|---|---|
| | | **Analysis 1** | | **Analysis 2** | |
| | | **Chemo/RT (n = 44)** | **Surgery (n = 33)** | **NA/Adj CHT + RT (n=23)** | **NACT + surgery (n=10)** |
| Age at diagnosis | Median (IQR) | 72 (64 –76) | 69 (59–74) | 69 (59–74) | 69 (62–79) |
| Sex, n (%) | F | 14 (31.8) | 5 (15.2) | 9 (39.1) | 2 (20.0) |
| | M | 30 (68.2) | 28 (84.8) | 14 (60.9) | 8 (80.0) |
| Stage groupings, n (%) | I/II | 11 (25.0) | 25 (75.8) | 2 (8.7) | 9 (90.0) |
| | III/IV | 31 (70.5) | 6 (18.2) | 20 (87.0) | 1 (10.0) |
| | X | 2 (4.5) | 2 (6.1) | 1 (4.3) | 0 (0.0) |
| TNM stage subgroups | T1N0 | 0 (0.0) | 3 (9.1) | 0 (0.0) | 0 (0.0) |
| | T2N0 | 11 (25.0) | 18 (54.5) | 1 (4.3) | 8 (80.0) |
| | T3N0 | 13 (29.5) | 3 (9.1) | 8 (34.8) | 1 (10.0) |
| | T4N0 | 4 (9.1) | 0 (0.0) | 4 (17.4) | 0 (0.0) |
| | Tx N0 | 0 (0.0) | 1 (3.0) | 0 (0.0) | 1 (10.0) |
| | T1 N (+) | 2 (4.5) | 0 (0.0) | 1 (4.3) | 0 (0.0) |
| | T2 N (+) | 1 (2.3) | 2 (6.1) | 1 (4.3) | 0 (0.0) |
| | T3 N (+) | 9 (20.5) | 1 (3.0) | 4 (17.4) | 0 (0.0) |
| | T4 N (+) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| | Tx N (+) | 1 (2.3) | 0 (0.0) | 1 (4.3) | 0 (0.0) |
| | T1 Nx | 1 (2.3) | 0 (0.0) | 1 (4.3) | 0 (0.0) |

| | | | | | |
|---|---|---|---|---|---|
| | T2 Nx | 1 (2.3) | 3 (9.1) | 1 (4.3) | 0 (0.0) |
| | T3 Nx | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| | T4 Nx | 1 (2.3) | 0 (0.0) | 1 (4.3) | 0 (0.0) |
| | Tx Nx | 0 (0.0) | 2 (6.1) | 0 (0.0) | 0 (0.0) |
| Dx small cell | On TURB | 44 (100) | 24 (73) | 23 (100) | 10 (100) |
| | Cystectomy only | 0 (0) | 9 (27) | 0 (0) | 0 (0) |
| ECOG, n (%) | 0/1 | 22 (50.0) | 24 (72.7) | 13 (56.5) | 9 (90.0) |
| | 2/3 | 20 (45.5) | 8 (24.2) | 10 (43.5) | 1 (10.0) |
| | Missing | 2 (4.5) | 1 (3.0) | 0 (0.0) | 0 (0.0) |
| Charlson comorbidity index, n (%) | 0–4 | 13 (29.5) | 15 (45.5) | 9 (39.1) | 5 (50.0) |
| | 5–7 | 25 (56.8) | 18 (54.5) | 13 (56.5) | 5 (50.0) |
| | 8–10 | 6 (13.6) | 0 (0.0) | 1 (4.3) | 0 (0.0) |
| Diagnosis year (%) | 1988–2007 | 29 (65.9) | 11 (33.3) | 17 (73.9) | 1 (10.0) |
| | 2008–2018 | 15 (34.1) | 22 (66.7) | 6 (26.1) | 9 (90.0) |
| Chemotherapy regimen, n (%) | Carboplatin-based | 12 (27.3) | 5 (15.2) | 5 (21.7) | 3 (30.0) |
| | Cisplatin-based | 29 (65.9) | 22 (66.7) | 16 (69.6) | 7 (70.0) |
| | Other | 2 (4.5) | 0 (0.0) | 2 (8.7) | 0 (0.0) |
| | None | 1 (2.3) | 6 (18.2) | 0 (0.0) | 0 (0.0) |
| Adjuvant/neoadjuvant chemo, n (%) | Concurrent only | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| | Neoadjuvant ± concurrent | 37 (84.1) | 10 (30.3) | 19 (82.6) | 10 (100.0) |
| | Adjuvant ± concurrent | 6 (13.6) | 16 (48.5) | 4 (17.4) | 0 (0.0) |

| | | | | | |
|---|---|---|---|---|---|
| | None | 1 (2.3) | 7 (21.2) | 0 (0.0) | 0 (0.0) |
| Prophylactic cranial irradiation, n (%) | No | 37 (84.1) | 32 (97.0) | 18 (78.3) | 10 (100.0) |
| | Yes | 7 (15.9) | 1 (3.0) | 5 (21.7) | 0 (0.0) |

ECOG: Eastern Cooperative Oncology Group; F: female; M: male; TURBT: transurethral resection of the bladder tumor.

| Table 2. Analysis 1: Univariate analysis for overall survival and cancer-specific survival | | | | | | |
|---|---|---|---|---|---|---|
| **Variables** | **Overall survival** | | | **Cause-specific survival** | | |
| | **Hazard ratio** | **95% CI** | **p** | **Hazard ratio** | **95% CI** | **p** |
| Treatment group | | | | | | |
| Chemo RT | 1 | | | 1 | | |
| Primary surgery | 1.19 | 0.71–2.00 | 0.51 | 1.39 | 0.79–2.59 | 0.29 |
| Sex | | | | | | |
| Female | 1 | | | 1 | | |
| Male | 1.44 | 0.78–2.67 | 0.25 | 2.02 | 0.85–4.82 | 0.11 |
| Stage | | | | | | |
| I & II | 1 | | | 1 | | |
| III & IV | 0.69 | 0.40–1.20 | 0.19 | 0.76 | 0.42–1.45 | 0.41 |
| Unknown | 1.78 | 0.62–5.11 | 0.28 | 1.17 | 0.27–5.03 | 0.83 |
| ECOG | | | | | | |
| 0 | 1 | | | 1 | | |
| 1 | 1.98 | 0.98–4.00 | 0.058 | 2.62 | 0.99–6.96 | 0.054 |
| 2 | 1.85 | 0.84–4.06 | 0.12 | 2.79 | 0.96–8.09 | 0.059 |
| 3 | 2.67 | 0.83–8.58 | 0.1 | 2.18 | 0.42–11.34 | 0.36 |
| Charlson comorbidity index | | | | | | |
| 0–4 | 1 | | | 1 | | |
| 5–7 | 1.69 | 0.95–3.03 | 0.075 | 1.88 | 0.92–3.80 | 0.08 |
| 8–10 | 5.04 | 1.91–13.30 | 0.001 | 3.21 | 0.86–11.92 | 0.08 |
| Diagnosis year (Median split) | | | | | | |
| 1988–2007 | 1 | | | 1 | | |
| 2008–2016 | 0.9 | 0.52–1.56 | 0.72 | 1.18 | 0.63–2.21 | 0.6 |
| Chemotherapy regimen | | | | | | |

| | | | | | | |
|---|---|---|---|---|---|---|
| Carboplatin-based | 1 | | | 1 | | |
| Cisplatin-based | 0.93 | 0.48–1.79 | 0.82 | 1.05 | 0.47–2.33 | 0.9 |
| None | 1.93 | 0.76–4.91 | 0.17 | 2.29 | 0.79–6.61 | 0.13 |
| Other | 1.12 | 0.25–5.05 | 0.89 | 1.03 | 0.13–8.27 | 0.98 |
| Adjuvant/Neoadjuvant | | | | | | |
| Adjuvant | 1 | | | 1 | | |
| Neoadjuvant | 0.6 | 0.34–1.05 | 0.07 | 0.6 | 0.3 –1.05 | 0.11 |
| None | 1.63 | 0.71–3.75 | 0.25 | 1.76 | 0.70–4.43 | 0.23 |
| Age at diagnosis | 1.01 | 0.98–1.04 | 0.43 | 1 | 0.97–1.03 | 0.96 |

ECOG: Eastern Cooperative Oncology Group; CI: confidence interval; RT: radiation therapy.

| Table 3. Analysis 1: Multivariate analysis for overall survival | | | |
|---|---|---|---|
| **Variables** | **Hazard ratio** | **95% CI** | **p** |
| Treatment group | | | |
|   Chemo RT | 1 | | |
|   Primary surgery | 1.09 | 0.52–2.27 | 0.82 |
| Stage | | | |
|   I & II | 1 | | |
|   III & IV | 0.99 | 0.49–1.98 | 0.97 |
|   Unknown | 2.02 | 0.68–6.02 | 0.21 |
| Charlson comorbidity index | | | |
| 0–4 | 1 | | |
| 5–7 | 1.58 | 0.83–3.01 | 0.16 |
| 8–10 | 6.82 | 2.15–21.7 | 0.001 |
| Adjuvant/neoadjuvant | | | |
|   Adjuvant | 1 | | |
|   Neoadjuvant | 0.50 | 0.26–0.97 | **0.04** |
|   None | 1.39 | 0.58–3.37 | 0.46 |

CI: confidence interval; RT: radiation therapy.

| Table 4. Analysis 1: Multivariate analysis for cancer-specific survival | | | |
|---|---|---|---|
| **Variables** | **Hazard ratio** | **95% CI** | **p** |
| Treatment group | | | |
|   Chemo RT | 1 | | |
|   Primary surgery | 1.78 | (0.66–4.79) | 0.26 |
| Stage | | | |
|   I & II | 1 | | |
|   III & IV | 1.07 | (0.44–2.60) | 0.88 |
|   Unknown | 1.23 | (0.27–5.60) | 0.79 |
| Charlson comorbidity index | | | |
|   0–4 | 1 | | |
|   5–7 | 2.06 | (0.90–4.71) | 0.09 |
|   8–10 | 5.75 | (1.15–28.7) | **0.03** |
| ECOG | | | |
|   0 | 1 | | |
|   1 | 3.09 | (1.06–8.98) | **0.04** |
|   2 | 2.92 | (0.89–9.59) | 0.08 |
|   3 | 1.84 | (0.29–11.6) | 0.52 |
| **Adjuvant/neoadjuvant** | | | |
|   Adjuvant | 1 | | |
|   Neoadjuvant | 0.51 | 0.21–1.21 | 0.12 |
|   None | 0.87 | 0.30–2.53 | 0.79 |

ECOG: Eastern Cooperative Oncology Group; CI: confidence interval; RT: radiation therapy.